Prevention of Vertical Transmission of HIV: Strategies, Successes, and Failures

  • Philippe Van de Perre
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 503)

Abstract

In this presentation, I would like to review what is working and what is apparently not working as tools to combat Mother-to-Child Transmission (MTCT) of HIV. With only 10% of the world population, Africa has more than 60% of the world’s people living with HIV and more than 90% of children with the virus are living in Sub Saharan Africa. It would take 8 years in the United States to reach the number of infants and children infected with HIV each day in developing countries.

Keywords

Placebo Europe Palmitate Zidovudine Retinol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simonon A, Lepage P, Karita E, et al. An assessment of the timing of mother-to-child tranmission of human immunodeficiency virus type 1 by means of polymerase chain reaction. J Acquir Immune Def Syndr 1994; 7: 952–7.Google Scholar
  2. 2.
    Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimavalye LA, Van der Hoeven L, Chiphangwi JD, Liomba G, Biggar RJ. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999;282:744–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Leroy V, Newell ML, Dabis F, Peckham C, Van de Perre P, Bulterys M, Kind C, Simonds RJ, Wiktor S, Msellati P, for the Ghent International Working Group on Mother-to-Child Transmission of HIV. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998; 352: 597–600.PubMedCrossRefGoogle Scholar
  4. 4.
    Coutsoudis A., Pillay K., Spooner E., Kuhn L., Coovadia H.M. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcome and early mother-to-child transmission in Durban, South Africa. South African Vitamin A Study Group. AIDS 1999; 13: 1517–24.PubMedCrossRefGoogle Scholar
  5. 5.
    European Mode of Delivery Collaborative Study. Elective caesarean —section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035–9.CrossRefGoogle Scholar
  6. 6.
    Mandelbrot L., Le Chenadec J., Berrebi A., et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280: 55–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Nduati R. Clinical studies of breast versus formula feeding. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mother to Child, Montreal, Canada, septembre 1999. Presentation # 047.Google Scholar
  8. 8.
    Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM for the South African Vitamin A Study Group. Influence of infant feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa. Lancet 1999; 353: 354:471–76.CrossRefGoogle Scholar
  9. 9.
    Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, Mtimavalye L, Biggar RI, Broadhead R, Miotti PG, Sokoll LJ, van der Hoeven L, Chiphangwi JD. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180: 93–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Connor ED, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with ZDV treatment. N Engl J Med 1994; 331: 1173–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. Six months efficacy, tolerance and acceptability of a short regimen of oral zidovudine in reducing vertical transmission of HIV in breast-fed children. A double blind placebo controlled multicentre trial, ANRSO49a, Côte d’Ivoire and Burkina Faso. Lancet 1999;353:786–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Wiktor S, Ekpini E, Karon J, Nkengasong J, Maurice C, Severin S, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomized trial. Lancet 1999;353:781–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.PubMedGoogle Scholar
  15. 15.
    Marseille E., Kahn J., Mmiro F., et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999;354:803–9.PubMedGoogle Scholar
  16. 16.
    Wade NA, Birkhead GS, Warren BL, et al.Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Wiktor S.Z., Leroy V., Ekpini E.R., et al. 24-month efficacy of short-course maternal zidovudine for the prevention of mother-to-child HIV-1 transmission in a breast feeding population. A pooled analysis of two randomized clinical trials in West Africa. 13thInternational AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstract TuOrB354.Google Scholar
  18. 18.
    Gray G. for the PETRA Trial Management Committee. The Petra study: early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1. 13th International AIDS Conference, Durban, South Africa, 9–14 July 2000. Abstract LbOrS.Google Scholar
  19. 19.
    Welles S.L., Pitt J., Colgrove R. et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 2000; 14: 263–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Beker-Pergola G., Guay L., Mmiro F., et al. Selection of the K103N Nevirapine resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-006). 7thConference on Retroviruses and Opportunistic Infections, San Francisco, Jan 30-Feb 2 2000.Google Scholar
  21. 21.
    Jackson J.B., Mracna M., Guay L., et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET012). 13th International AIDS Conference, Durban, South Africa, 9–14 July 2000.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Philippe Van de Perre
    • 1
  1. 1.Centre Muraz/OCCGEBobo-DioulassoBurkina Faso

Personalised recommendations